The analysis of the innate pathways of 5-fluorouracil phosphorylation in human gastrointestinal cancer cell lines in vitro and in vivo

Oncology Reports

Volumn 4, Issue 6, 1997, Pages 1189-1194

  Fukushima, Masakazu ^a   Murakami, Yuko ^a   Suzuki, Norihiko ^a   Aiba, Keisuke ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

2,6 dihydroxypyridine; 5 fluorouracil; 5 fluorouracil phosphorylation; Metabolic pathway; Oxonic acid

Indexed keywords

2,6 DIHYDROXYPYRIDINE; ENZYME INHIBITOR; FLUOROURACIL; FLUOROURIDINE; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXONIC ACID; PHOSPHORIBOSYL PYROPHOSPHATE; URIDINE PHOSPHORYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PHOSPHORYLATION; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; TUMOR XENOGRAFT;

EID: 0030883862     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.4.6.1189     Document Type: Article

References (32)

1. Kemeny N: Current approaches to metastatic colorectal cancer. Semin Oncol 21: 67-75, 1994.
2. Doroshow JH, Multhauf P, Leong L, Margolink K, Litchfield T, Akman S, Carr B, Bertrand M, Goldbelg D, Odujinrin O, Delap R, Shuster J and Newman E: Prospective randomized comparison of fluorouracil versus fluprouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8: 491-501, 1990.
3. Ehrlichman C, Fines S, Wong A and Elhakim T: Randomized trial of fiuorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469-475, 1988.
4. O'Connell MJ: A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Cancer 63: 1026-1030, 1989.
5. Petrelli N, Douglass HO, Herrera L, et al: For the Gastrointestinal Tumor Study Group: the modulation of 5-fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7: 1419-1426, 1989.
6. Cantrell JE, Hart RD, Tayler RF and Harvey JH Jr: Pilot trial of prolonged continuous infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer. Cancer Treat Rep 71: 615-618, 1987.
7. Kemeny N, Israel K, Niedzwieck D, Chapman D, Botet J, Minsky B, Vinciguerra V, Rosenbluth R, Bosselli B, Cochran C and Sheehan K: Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J Clin Oncol 8: 313-318, 1990.
8. LoRusso P, Pazdur R, Redman BG, Kinzie J and Vaitkevicius V: Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma. Am J Clin Oncol 12: 486-490, 1989.
9. Kish JA, Ensley JF, Jacob JR, Binns P and Al-Sarraf M: Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer. Am J Clin Oncol 11: 553-557, 1988.
10. Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J and Al-Sarraf M: Improved complete response rates and survival in advanced head and neck cancer after three-course induction therapy with 120 h 5-FU infusion and cisplatin. Cancer 55: 1123-1128, 1985.
11. Thomas GD and Paterson ICM: Response rates and survival in patients with head and neck cancer treated with a combination of cisplatin and 5-fluorouracil prior to radiotherapy. Clin Radiol 39: 551-554, 1988.
12. Weaver A, Fleming S, Ensley J, Kinzie J, Crissman J and AlSarraf M: Superior clinical response and survival rates with initial bolus cisplatin and 120 h infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer. Am J Surg 148: 525-529, 1984.
13. Hartman KY and Heidelberger C: Studies on fluorinated pyrimidines: XIII. Inhibition of thymidylate synthase. J Biol Chem 236: 3006-3018, 1961.
14. Langenback RJ, Danenberg PV and Heidelberger C: Thymidylate synthase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun 48: 1565-1571, 1972.
15. Santi DV and McHenry CS: 5-Fluoro-2′-deoxyuridylate: covalent complex with thymidylate synthase. Proc Natl Acad Sci USA 69: 1855-1857, 1972.
16. Spears CP, Shahinian AH, Moran RG, Heidelberger C and Corbett TH: In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and resistant murine colon adenocarcinomas. Cancer Res 43: 450-456, 1982.
17. Carrico CK and Glazer RI: Effect of 5-fluorouracil on the synthesis and translation of polyadenylic acid-containing RNA from regenerating rat liver. Cancer Res 39: 3694-3701, 1979.
18. Doong S-L and Dolnick BJ: 5-Fluorouracil substitution alters pre-mRNA splicing in vitro. J Biol Chem 236: 4467-4473, 1988.
19. Glazer RI and Lloyd LS: Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol Pharmacol 21: 468-475, 1982.
20. Greenhalgh DA and Parish JH: Effect of 5-fluorouracil on cytotoxicity and RNA metabolism in human colonic carcinoma cells. Cancer Chemother Pharmacol 25: 37-44, 1989.
21. Wilkinson DS, Tlsty TD and Hanas RJ: The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine. Cancer Res 35: 3014-3020, 1975.
22. Maehara Y, Nagayama S, Okazaki H, Nakamura H, Shirasaka T and Fujii S: Metabolism of 5-fluorouracil in various human normal and tumor tissues. Gann 72: 824-827, 1981.
23. Houghton JA and Houghton PJ: Elucidation of pathway of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma. Eur J Clin Oncol 19: 807-815, 1983.
24. Tatsumi K, Fukushima M, Shirasaka T and Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78: 748-755, 1987.
25. Shirasaka T, Shimamoto Y and Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004-4009, 1993.
26. Park JG, Oie HK, Sugarbaker PH, Henslee JG, Chen T-R, Johnson BE and Gazdar A: Characteristics of cell lines established from human colorectal carcinoma. Cancer Res 47: 6710-6718, 1987.
27. Schneider CW: Phosphorous compounds in animal tissues. III. comparison of methods for the estimation of nucleic acid. J Biol Chem 164: 747-751, 1946.
28. Hisata T: An accurate method for estimating 5-phosphoribosyl 1-pyrophosphate in animal tissue with the use of acid extraction. Anal Biochem 68: 448-457, 1975.
29. Wadler S, Lembersky B, Atkins M, Kirkwood J and Petrelli N: Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 9: 1806-1810, 1991.
30. Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V and Wiernik PH: Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 7: 1769-1775, 1989.
31. Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B, DuBrow R, Campos L, Quaraishi M, Faintuch J, Abbruzzese JL, Gutterman J and Levin B: Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 8: 2027-2031, 1990.
32. Schwartz EL, Baptiste N, Wadler S and Makower D: Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 270: 19073-19077, 1995.